Glucagon receptor agonist

Last updated

Glucagon receptor agonists are a class of drugs under development for the treatment of obesity, non-alcoholic fatty liver disease, and congenital hyperinsulinism.

Contents

Background

Glucagon is a hormone that generally opposes the action of insulin. [1] It increases blood glucose by stimulating the production of glucose in the liver via glycogenolysis (breakdown of glycogen) and gluconeogenesis (production of glucose from non-carbohydrate sources). [2] Glucagon also increases the breakdown of lipids and amino acids and the production of ketones. [3] [4] In healthy people, a low dose of exogenous glucagon increases energy expenditure and reduces energy intake without causing hyperglycemia. [2] Glucagon is often elevated in type 2 diabetes; [3] glucagon receptor antagonists were developed for the treatment of this disease but most were abandoned due to safety and adverse effects. [2]

Therapeutic uses

Rescue glucagon has been a preferred treatment for hypoglycemic shocks in insulin-dependent diabetes since the 1960s, but its use is limited by lack of stability. In the twenty-first century drug development has focused on making more stable versions, some of which do not require injection. [5] [3] [6]

The glucagon receptor agonist HM15136 is in clinical trials for congenital hyperinsulinism. [2]

Unlike currently approved weight loss drugs, glucagon receptor agonists increase energy expenditure. [7]

Combination therapies

Combinations of glucagon with other incretin analogues such as GLP-1 receptor agonists and/or GIP receptor agonists is hoped to provide enhanced weight loss and metabolic improvements with fewer adverse effects. [7] Combination GLP-1/glucagon receptor agonists provide the thermogenic benefits of glucagon activation while almost eliminating hyperglycemia induced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse effects have hampered development. [2]

Glucagon is also a tissue-selective delivery mechanism for small molecule drugs. [2] The glucagon-T3 conjugate in mice delivers significant metabolic benefits with less toxicity than glucagon or T3. [2] [8]

Adverse effects

Hyperglycemia is one of the major adverse effects associated with glucagon receptor activation. Although glucagon receptors are densest in the liver, they also appear in other organs including the heart. Glucagon receptor agonists can increase heart rate, although cardiac risks may be mitigated by more tissue selective agonists with a preference for the liver. [2]

Related Research Articles

<span class="mw-page-title-main">Glucagon</span> Peptide hormone

Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It raises the concentration of glucose and fatty acids in the bloodstream and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. Its effect is opposite to that of insulin, which lowers extracellular glucose. It is produced from proglucagon, encoded by the GCG gene.

Drugs used in diabetes treat diabetes mellitus by altering the glucose level in the blood. With the exception of insulin, most GLP receptor agonists, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of diabetes, age, and situation of the person, as well as other factors.

<span class="mw-page-title-main">Anti-obesity medication</span> Class of pharmacological agents

Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body, weight regulation, by reducing appetite and consequently energy intake, increasing energy expenditure, redirecting nutrients from adipose to lean tissue, or interfering with the absorption of calories.

Oxyntomodulin is a naturally occurring 37-amino acid peptide hormone found in the colon, produced by the oxyntic (fundic) cells of the oxyntic (fundic) mucosa. It has been found to suppress appetite.

Enteroglucagon is a peptide hormone derived from preproglucagon. It is a gastrointestinal hormone, secreted from mucosal cells primarily of the colon and terminal ileum. It consists of 37 amino acids. Enteroglucagon is released when fats and glucose are present in the small intestine; which decrease the motility to allow sufficient time for these nutrients to be absorbed.

<span class="mw-page-title-main">Exenatide</span> Medication

Exenatide, sold under the brand name Byetta and Bydureon among others, is a medication used to treat diabetes mellitus type 2. It is used together with diet, exercise, and potentially other antidiabetic medication. It is a treatment option after metformin and sulfonylureas. It is given by injection under the skin twice daily or once weekly.

<span class="mw-page-title-main">Dipeptidyl peptidase-4 inhibitor</span> Enzyme blocker and diabetes treatment drug

Inhibitors of dipeptidyl peptidase 4 are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2.

<span class="mw-page-title-main">Glucagon-like peptide-1</span> Gastrointestinal peptide hormone Involved in glucose homeostasis

Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region.

<span class="mw-page-title-main">Glucagon-like peptide-1 receptor</span> Receptor activated by peptide hormone GLP-1

The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion. In humans it is synthesised by the gene GLP1R, which is present on chromosome 6. It is a member of the glucagon receptor family of GPCRs. GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1, and one transmembrane (TMD) domain that binds the N-terminal region of GLP-1. In the TMD domain there is a fulcrum of polar residues that regulates the biased signaling of the receptor while the transmembrane helical boundaries and extracellular surface are a trigger for biased agonism.

<span class="mw-page-title-main">Free fatty acid receptor 1</span> Protein-coding gene in the species Homo sapiens

Free fatty acid receptor 1 (FFAR1), also known as G-protein coupled receptor 40 (GPR40), is a rhodopsin-like G-protein coupled receptor that is coded by the FFAR1 gene. This gene is located on the short arm of chromosome 19 at position 13.12. G protein-coupled receptors reside on their parent cells' surface membranes, bind any one of the specific set of ligands that they recognize, and thereby are activated to trigger certain responses in their parent cells. FFAR1 is a member of a small family of structurally and functionally related GPRs termed free fatty acid receptors (FFARs). This family includes at least three other FFARs viz., FFAR2, FFAR3, and FFAR4. FFARs bind and thereby are activated by certain fatty acids.

<span class="mw-page-title-main">Liraglutide</span> Anti-diabetic medication

Liraglutide, sold under the brand names Victoza and Saxenda among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.

Albiglutide is a glucagon-like peptide-1 agonist drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. GSK has announced that it intends to withdraw the drug from the worldwide market by July 2018 for economic reasons.

Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, are a class of drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1 that is released by the gut after eating.

<span class="mw-page-title-main">Dulaglutide</span> Diabetes medication

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.

Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It was developed by Novo Nordisk in 2012 and approved for use in the US in 2017. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold under the brand names Ozempic (injectable) and Rybelsus (pill) for diabetes, and under the brand name Wegovy for weight loss.

Cotadutide is an experimental drug for the treatment of type 2 diabetes mellitus. It lowers blood glucose levels by mimicking the human hormones glucagon-like peptide 1 and glucagon, which play a role in blood sugar regulation. The drug is a peptide that is injected under the skin.

Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes.

<span class="mw-page-title-main">Tirzepatide</span> Anti-diabetic medication

Tirzepatide, sold under the brand name Mounjaro among others, is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered through subcutaneous injection.

NNC9204-1706 or NN9423 is a GLP-1/GIP/glucagon receptor triple agonist developed by Novo Nordisk. It was evaluated in a clinical trial; adverse effects such as "dose-dependent increases in heart rate and reductions in reticulocyte count, increases in markers of inflammation and hepatic disturbances, and impaired glucose tolerance at the highest dosages" meant that the drug was declared to have an inadequate safety profile and discontinued.

GLP1 poly-agonist peptides are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. They are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors.

References

  1. ↑ Finan, Brian; Capozzi, Megan E.; Campbell, Jonathan E. (1 April 2020). "Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes". Diabetes. 69 (4): 532–541. doi: 10.2337/dbi19-0004 . PMC   7085250 . PMID   31178432.
  2. 1 2 3 4 5 6 7 8 Novikoff, Aaron; Müller, Timo D. (2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165: 171003. doi: 10.1016/j.peptides.2023.171003 . ISSN   0196-9781. PMC   10265134 . PMID   36997003.
  3. 1 2 3 Patil, Mohan; Deshmukh, Nitin J.; Patel, Mahesh; Sangle, Ganesh V. (May 2020). "Glucagon-based therapy: Past, present and future". Peptides. 127: 170296. doi:10.1016/j.peptides.2020.170296. PMID   32147318. S2CID   212408895.
  4. ↑ Capozzi, Megan E.; D’Alessio, David A.; Campbell, Jonathan E. (2022). "The past, present and future physiology and pharmacology of glucagon". Cell Metabolism. 34 (11): 1654–1674. doi: 10.1016/j.cmet.2022.10.001 . ISSN   1550-4131. PMC   9641554 . PMID   36323234.
  5. ↑ Hughes, Allyson S.; Chapman, Katherine S.; Nguyen, Huyen; Liu, Jingwen; Bispham, Jeoffrey; Winget, Melissa; Weinzimer, Stuart A.; Wolf, Wendy A. (1 July 2023). "Severe Hypoglycemia and the Use of Glucagon Rescue Agents: An Observational Survey in Adults With Type 1 Diabetes". Clinical Diabetes. 41 (3): 399–410. doi:10.2337/cd22-0099. PMC   10338275 . PMID   37456102.
  6. ↑ Chabenne, Joseph R.; Mroz, Piotr A.; Mayer, John P.; DiMarchi, Richard D. (9 April 2020). "Structural Refinement of Glucagon for Therapeutic Use". Journal of Medicinal Chemistry. 63 (7): 3447–3460. doi:10.1021/acs.jmedchem.9b01493. PMID   31774682. S2CID   208335773.
  7. 1 2 Sánchez-Garrido, Miguel A.; Brandt, Sara J.; Clemmensen, Christoffer; Müller, Timo D.; DiMarchi, Richard D.; Tschöp, Matthias H. (2017). "GLP-1/glucagon receptor co-agonism for treatment of obesity". Diabetologia. 60 (10): 1851–1861. doi: 10.1007/s00125-017-4354-8 . PMC   6448809 . PMID   28733905.
  8. ↑ Ghaben, Alexandra L.; Scherer, Philipp E. (3 March 2017). "Pas de Deux: Glucagon and Thyroid Hormone Moving in Perfect Synchrony". Circulation Research. 120 (5): 762–764. doi: 10.1161/CIRCRESAHA.117.310452 . ISSN   0009-7330. PMC   5338644 . PMID   28254797.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.